

# US Patent & Trademark Office

## Patent Public Search | Text View

---

United States Patent Application Publication

20250263707

Kind Code

A1

Publication Date

August 21, 2025

Inventor(s)

THOMPSON; Bradley G.

---

### COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

---

#### Abstract

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.

---

**Inventors:** THOMPSON; Bradley G. (Calgary, CA)

**Applicant:** Wyvern Pharmaceuticals Inc. (Calgary, CA)

**Family ID:** 1000007743045

**Appl. No.:** 18/582317

**Filed:** February 20, 2024

---

#### Publication Classification

**Int. Cl.:** C12N15/113 (20100101); C12N15/86 (20060101)

**U.S. Cl.:**

**CPC** C12N15/1137 (20130101); C12N15/86 (20130101); C12N2310/141 (20130101);  
C12N2750/14143 (20130101)

---

## Background/Summary

[0001] This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an XML Document file entitled "A8149442US-Sequence Listing.xml" created on 2024 Feb. 12 and having a size of 76,125 bytes. The information contained in the Sequence Listing is incorporated by reference herein.

### TECHNICAL FIELD

[0002] The present disclosure generally relates to compositions for regulating production of interfering ribonucleic acid (RNA). In particular, the present disclosure relates to compositions for regulating gene expression and therefore, the production of interfering RNA that will suppress complement or factor expression.

### BACKGROUND

[0003] Bioactive molecules, including complements and factors, are necessary for the homeostatic control of biological systems.

[0004] When bioactive molecules are over-expressed, under-expressed or mis-expressed, homeostasis is lost, and disease is often the result.

[0005] As such, it may be desirable to establish therapies, treatments and/or interventions that address when homeostasis and regulation of bioactive molecules is lost to prevent or treat the resulting disease.

### SUMMARY

[0006] Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1r. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1s. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C3. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor D. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor 10.

[0007] In some embodiments of the present disclosure the compositions comprise a plasmid of deoxyribonucleic acid (DNA) that includes one or more insert sequences of nucleic acids that encode for the production of miRNA and a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated. Expression of the one or more insert sequences by one or more cells of the subject results in an increased production of the miRNA and, therefore, decreased translation or production of the target biomolecule by one or more of the subject's cells.

[0008] Some embodiments of the present disclosure relate to compositions that upregulate the production of miRNA that degrades, or causes degradation of, or inactivates or causes the inactivation of, the mRNA of the target biomolecule.

[0009] Some embodiments of the present disclosure relate to a recombinant plasmid (RP). In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 2. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of complement C1q.

[0010] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 3. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of complement C1r.

[0011] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 4. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of complement C1s.

[0012] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 5. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of complement C3.

[0013] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 6. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of complement C5.

[0014] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 7. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of Factor B.

[0015] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 8. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of Factor D.

[0016] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 9. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets the mRNA of Factor 10.

[0017] Some embodiments of the present disclosure relate to a method of making a composition/target cell complex. The method comprising a step of administering a RP comprising SEQ ID NO. 1 and one of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, or SEQ ID NO. 9 to a target cell for forming the composition/target cell complex, wherein the composition/target cell complex causes the target cell to increase production of one or more sequences of miRNA that decreases production of a target biomolecule.

[0018] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example complement C1q. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of complement C1q, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0019] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example complement C1r. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of

miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of complement C1r, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0020] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example complement C1s. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of complement C1s, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0021] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example complement C3. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of complement C3, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0022] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example complement C5. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of complement C5, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0023] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example Factor B. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of Factor B, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0024] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example Factor D. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of Factor D, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0025] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence the mRNA of a target biomolecule, for example Factor 10. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of Factor 10, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

---

## Description

## DETAILED DESCRIPTION

[0026] Unless defined otherwise, all technical and scientific terms used therein have the meanings that would be commonly understood by one of skill in the art in the context of the present description. Although any methods and materials similar or equivalent to those described therein can also be used in the practice or testing of the present disclosure, the preferred compositions, methods and materials are now described. All publications mentioned therein are incorporated therein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0027] As used therein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, reference to “a composition” includes one or more compositions and reference to “a subject” or “the subject” includes one or more subjects.

[0028] As used therein, the terms “about” or “approximately” refer to within about 25%, preferably within about 20%, preferably within about 15%, preferably within about 10%, preferably within about 5% of a given value or range. It is understood that such a variation is always included in any given value provided therein, whether or not it is specifically referred to.

[0029] As used therein, the term “ameliorate” refers to improve and/or to make better and/or to make more satisfactory.

[0030] As used therein, the term “cell” refers to a single cell as well as a plurality of cells or a population of the same cell type or different cell types. Administering a composition to a cell includes in vivo, in vitro and ex vivo administrations and/or combinations thereof.

[0031] As used therein, the term “complex” refers to an association, either direct or indirect, between one or more particles of a composition and one or more target cells. This association results in a change in the metabolism of the target cell. As used therein, the phrase “change in metabolism” refers to an increase or a decrease in the one or more target cells' production of one or more proteins, and/or any post-translational modifications of one or more proteins.

[0032] As used therein, the term “composition” refers to a substance that, when administered to a subject, causes one or more chemical reactions and/or one or more physical reactions and/or one or more physiological reactions and/or one or more biological reactions in the subject. In some embodiments of the present disclosure, the composition is a plasmid vector.

[0033] As used therein, the term “endogenous” refers to the production and/or modification of a molecule that originates within a subject.

[0034] As used therein, the term “exogenous” refers to a molecule that is within a subject but that did not originate within the subject. As used therein, the terms “production”, “producing” and “produce” refer to the synthesis and/or replication of DNA, the transcription of one or more sequences of RNA, the translation of one or more amino acid sequences, the post-translational modifications of an amino acid sequence, and/or the production of one or more regulatory molecules that can influence the production and/or functionality of an effector molecule or an effector cell. For clarity, “production” is also used therein to refer to the functionality of a regulatory molecule, unless the context reasonably indicates otherwise.

[0035] As used therein, the term “subject” refers to any therapeutic target that receives the composition. The subject can be a vertebrate, for example, a mammal including a human. The term “subject” does not denote a particular age or sex. The term “subject” also refers to one or more cells of an organism, an in vitro culture of one or more tissue types, an in vitro culture of one or more cell types, ex vivo preparations, and/or a sample of biological materials such as tissue, and/or biological fluids.

[0036] As used therein, the term “target biomolecule” refers to a complement or factor that is found within a subject. A biomolecule may be endogenous or exogenous to a subject and when bioavailable the biomolecule may inhibit or stimulate a biological process within the subject.

[0037] As used therein, the term “target cell” refers to one or more cells and/or cell types that are

deleteriously affected, either directly or indirectly, by a dysregulated biomolecule. The term “target cell” also refers to cells that are not deleteriously affected but that are the cells in which it is desired that the composition interacts.

[0038] As used therein, the term “therapeutically effective amount” refers to the amount of the composition used that is of sufficient quantity to ameliorate, treat and/or inhibit one or more of a disease, disorder or a symptom thereof. The “therapeutically effective amount” will vary depending on the composition used, the route of administration of the composition and the severity of the disease, disorder or symptom thereof. The subject's age, weight and genetic make-up may also influence the amount of the composition that will be a therapeutically effective amount.

[0039] As used therein, the terms “treat”, “treatment” and “treating” refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing an occurrence of a disease, disorder or symptom thereof and/or the effect may be therapeutic in providing a partial or complete amelioration or inhibition of a disease, disorder, or symptom thereof. Additionally, the term “treatment” refers to any treatment of a disease, disorder, or symptom thereof in a subject and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) ameliorating the disease.

[0040] As used therein, the terms “unit dosage form” and “unit dose” refer to a physically discrete unit that is suitable as a unitary dose for patients. Each unit contains a predetermined quantity of the composition and optionally, one or more suitable pharmaceutically acceptable carriers, one or more excipients, one or more additional active ingredients, or combinations thereof. The amount of composition within each unit is a therapeutically effective amount.

[0041] Where a range of values is provided therein, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also, encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0042] In some embodiments of the present disclosure, a composition is a recombinant plasmid (RP) for introducing genetic material, such as one or more nucleotide sequences, into a target cell for reproduction or transcription of an insert that comprises one or more nucleotide sequences that are carried within the RP. In some embodiments of the present disclosure, the RP is delivered without a carrier, by a viral vector, by a protein coat, or by a lipid vesicle. In some embodiments of the present disclosure, the vector is an adeno-associated virus vector.

[0043] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that encode for production of at least one sequence of miRNA that decreases the production of target biomolecules. The miRNA may, directly or indirectly, bind to and degrade the target mRNA or otherwise inactivate the target mRNA so that less or none of the target-biomolecule protein is produced.

[0044] In some embodiments of the present disclosure, the target biomolecule is the complement C1q.

[0045] In some embodiments of the present disclosure, the target biomolecule is the complement C1r.

[0046] In some embodiments of the present disclosure, the target biomolecule is the complement C1s.

[0047] In some embodiments of the present disclosure, the target biomolecule is the complement C3.

[0048] In some embodiments of the present disclosure, the target biomolecule is the complement

C5.

[0049] In some embodiments of the present disclosure, the target biomolecule is Factor B.

[0050] In some embodiments of the present disclosure, the target biomolecule is Factor D.

[0051] In some embodiments of the present disclosure, the target biomolecule is Factor 10.

[0052] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that each encode for one or more miRNA sequences that may be complimentary to and degrade, or cause degradation of, mRNA of the target biomolecule.

[0053] Some embodiments of the present disclosure relate to a composition that can be administered to a subject with a condition that results, directly or indirectly, from the dysregulated production of a biomolecule. When a therapeutically effective amount of the composition is administered to the subject, the subject may change production and/or functionality of one or more biomolecules.

[0054] In some embodiments of the present disclosure, the subject may respond to receiving the therapeutic amount of the composition by changing production and/or functionality of one or more intermediary molecules by changing production of one or more DNA sequences, one or more RNA sequences, and/or one or more proteins that regulate the levels and/or functionality of the one or more intermediary molecules. The one or more intermediary molecules regulate the subject's levels and/or functionality of the one or more biomolecules.

[0055] In some embodiments of the present disclosure, administering a therapeutic amount of the composition to a subject upregulates the production, functionality or both one or more sequences of miRNA that each target the mRNA of one or more target biomolecules. In some embodiments of the present disclosure, there are one, two, three, four, five, or six miRNA sequences that each are complimentary to and degrade, or cause degradation of, one biomolecule, such as the mRNA of complement C1q, complement C1r, complement C1s, complement C3, complement C5, Factor B, Factor D, or Factor 10. In some embodiments of the present disclosure, the composition may comprise multiple copies of the same nucleotide sequence of miRNA.

[0056] In some embodiments of the present disclosure, the composition is an RP that may be used for gene therapy. The gene therapy is useful for increasing the subject's endogenous production of one or more sequences of miRNA that target the mRNA of a target biomolecule. For example, the RP can contain one or more nucleotide sequences that cause increased production of one or more nucleotide sequences that cause an increased production of one or more miRNA sequences that are each complimentary to and degrade, or cause degradation of, or inactivate, or cause inactivation of, one biomolecule, such as complement C1q, complement C1r, complement C1s, complement C3, complement C5, Factor B, Factor D, or Factor 10.

[0057] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene therapy may be a vector that comprises a virus that can be enveloped, or not (unenveloped), replication effective or not (replication ineffective), or combinations thereof. In some embodiments of the present disclosure, the vector is a virus that is not enveloped and not replication effective. In some embodiments of the present disclosure, the vector is a virus of the Parvoviridae family. In some embodiments of the present disclosure, the vector is a virus of the genus Dependoparvovirus. In some embodiments of the present disclosure, the vector is an adeno-associated virus (AAV). In some embodiments of the present disclosure, the vector is a recombinant AAV. In some embodiments of the present disclosure, the vector is a recombinant AAV6.2FF.

[0058] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene therapy may be a protein coat.

[0059] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene therapy may be a lipid vesicle.

[0060] The embodiments of the present disclosure also relate to administering a therapeutically effective amount of the composition. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is between

about 10 and about 1×10<sup>sup.16</sup> TCID<sub>50</sub>/kg (50% tissue culture infective dose per kilogram of the patient's body mass). In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to the patient is about 1×10<sup>sup.13</sup> TCID<sub>50</sub>/kg. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is measured in TPC/kg (total particle count of the composition per kilogram of the patient's body mass). In some embodiments the therapeutically effective amount of the composition is between about 10 and about 1×10<sup>sup.16</sup> TCP/kg.

[0061] Some embodiments of the present disclosure relate to an adeno-associated virus (AAV) genome consisting of a RP that when operable inside a target cell will cause the target cell to produce a miRNA sequence that downregulates production of a biomolecule, with examples being complement C1q, complement C1r, complement C1s, complement C3, complement C5, Factor B, Factor D, or Factor 10. The RP is comprised of AAV2 inverted terminal repeats (ITRs), a composite CASI promoter, a human growth hormone (HGH) signal peptide followed by a miRNA expression cassette containing up to six different miRNAs targeting the mRNA of complement C1q, complement C1r, complement C1s, complement C3, complement C5, Factor B, Factor D, or Factor 10, followed by a Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE) and a Simian virus 40 (SV40) polyadenylation (polyA) signal.

TABLE-US-00001 SEQ ID NO. 1 (backbone sequence No. 1): 5'

AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT  
GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAG  
GAGTTGTGGCCCGTTGTTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA  
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTGCTT  
TCCCCCTCCCTATTGCCACGGCGGAATCATCGCCGCCTGCCTTGCCCGCTGCTGGA  
CAGGGGCTCGGCTGTTGGGCACTGACAATTCGTGGTGTTCGCGGGAATCATCGT  
CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
CTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCT  
CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
CCGCCTCCCCGCCTAAGCTTATCGATACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTT  
CACTGCATTCTAGTTGTGGTTTGTCCAACTCATCAATGTATCTTATCATGTCTGGAT  
CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATTA  
ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
TCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGGC  
TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGCAATGGCTG  
GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCTGTCTAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
TTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
TTTTGATTTATAAGGGATTTTGCCGATTTCCGGCCTATTGGTTAAAAAATGAGCTGATT  
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT



GCTTATACTTCTGTTCTTTGGTGGTTTCTCTGATTGCTCAATCCGTTGATGATA  
TTGACATGCTAGTTTTTACGATTACCGTTCATCGATTCTCTTGTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTAAAA  
TATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGATTTATTGGATGTTGGA  
ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATATGG  
TGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGTCAGAGGTTTTACCGTTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTGCGCCCTTATTCCTTTTTTGGCGGCATTTTGCCTTCTGTTTTTTGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACTATTCTCAGAATGACTTGGTTGAG  
TACTCACCGATCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAATC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGCGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGCGGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGGG  
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCGCGCCGGG  
CAAAGCCCCGGGCGTCGGGCGACCTTTGGTGCGCCCGGCCTCAGTGAGCGAGCGAGCG



CTCAGGACCAAGGCTGTTAGCACTCACATGGCAACAAATGGCCTCTAGCCTG  
GAGGCTTGCTGAAGGCTGTATGCTGAGATGAATGCCAAATAGCCTTCCGTTTTGGCC  
TCTGACTGACGGAAGGCTATGGCATTTCATCTCAGGACACAAGGCCTGTTACTAGCAC  
TCACATGGAACAAATGGCCTCTCTAGAAT 3' SEQ ID NO. 5 (miRNA expression  
cassette No. 5 - complement C3): 5'

GCCACCATGGCCACCGGCTCTCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGC  
CTGCCTTGGCTCCAGGAGGGCTCCGCCGCTAGCATCGATAACCGTCGCTATGTGCTGG  
AGGCTTGCTGAAGGCTGTATGCTGTTTCAGATCATCTGGGTATCCGGCGTTTTGGCCT  
CTGACTGACGCCGGATAACCGATGATCTGAACAGGACACAAGGCCTGTTACTAGCAC  
TCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGAATA  
ATCAGATGGTGTGCGATCGTTTTGGCCTCTGACTGACGATCGCAACACCCTGATTA  
TTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGG  
AGGCTTGCTGAAGGCTGTATGCTGTACTGATGCACAATTTAAACGCCGTTTTGGCCT  
CTGACTGACGGCGTTTAAAGTGCATCAGTACAGGACACAAGGCCTGTTACTAGCACT  
CACATGGAACAAATGGCCTCTCTAGAAT 3' SEQ ID NO. 6 (miRNA expression  
cassette No. 6 - complement C5): 5'

ATGGCCACCGGCTCTCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCT  
TGGCTCCAGGAGGGCTCCGCCGCTAGCATCGATAACCGTCGCTATGTGCTGGAGGCTT  
GCTGAAGGCTGTATGCTGAGGTAATCGGCTGATGCGTTTGCGTTTTGGCCTCTGACT  
GACGCAAACGCATGCCGATTACCTCAGGACACAAGGCCTGTTACTAGCACTCACAT  
GGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGTTATACACGG  
TATGCCTTTCAGCGTTTTGGCCTCTGACTGACGCTGAAAGGCACCGTGTATAACAGG  
ACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTT  
GCTGAAGGCTGTATGCTGATCAGATCATCAAGTTCAGCAGCGTTTTGGCCTCTGACT  
GACGCTGCTGAACGATGATCTGATCAGGACACAAGGCCTGTTACTAGCACTCACATG  
GAACAAATGGCCTCTCTAGAAT 3' SEQ ID NO. 7 (miRNA expression cassette  
No. 7 - Factor B): 5'

GCCACCATGGCCACCGGCTCTCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGC  
CTGCCTTGGCTCCAGGAGGGCTCCGCCGCTAGCATCGATAACCGTCGCTATGTGCTGG  
AGGCTTGCTGAAGGCTGTATGCTGACATAAAGCTATGTCCTGGCAGCGTTTTGGCCT  
CTGACTGACGCTGCCAGGATAGCTTTATGTCAGGACACAAGGCCTGTTACTAGCACT  
CACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGATACA  
GCAGATATCGCGAATTTGTTTTGGCCTCTGACTGACGAAATTCGCGATCTGCTGTA  
TCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGG  
AGGCTTGCTGAAGGCTGTATGCTGTTTCAGTTTAAATCAGCGCCACGTTTTGGCCT  
CTGACTGACGTGGCGCTGATTAAACTGAAACAGGACACAAGGCCTGTTACTAGCAC  
TCACATGGAACAAATGGCCTCTCTAGAAT 3' SEQ ID NO. 8 (miRNA expression  
cassette No. 8 - Factor D): 5'

GCCACCATGGCCACCGGCTCTCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGC  
CTGCCTTGGCTCCAGGAGGGCTCCGCCGCTAGCATCGATAACCGTCGCTATGTGCTGG  
AGGCTTGCTGAAGGCTGTATGCTGATACAGGCGTTTGTGCTCGGTTTCGTTTTGGCCTC  
TGACTGACGAACCGAGCAAACGCCTGTATCAGGACACAAGGCCTGTTACTAGCACT  
CACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGTCATG  
ATCAATATGGTATCCGGCGTTTTGGCCTCTGACTGACGCCGGATAACCATGATCATG  
ACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGG  
AGGCTTGCTGAAGGCTGTATGCTGTCATGATCAATAAGGTATCCGGCGTTTTGGCCT  
CTGACTGACGCCGGATAACCATGATCATGACAGGACACAAGGCCTGTTACTAGCACT  
CACATGGAACAAATGGCCTCTCTAGAAT 3' SEQ ID NO. 9 (miRNA expression  
cassette No. 9 - Factor 10): 5'

GCCACCATGGCCACCGGCTCTCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGC



TGCACTCTCAGTACATCAATGCTCTGATGCTCAGTATTAAGCCAGCCAGCCAGCCAGCC  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGTTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTCGCCCTTATTCCCTTTTTTTGCGGCATTTTGCCTTCCTGTTTTTTGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAG  
TACTCACAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTTGCACAACATGGGGGATCATGTAACCTC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACGTGCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACGTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTG TAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGCGGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGG  
AGCCTATGGA AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTTGCTGG  
CCTTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGG  
CAAAGCCCGGGCGTCGGGCGACCTTTGGTGCCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTTG TAGTTAATGATTAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG

TGCAGCAGTGGGCGGGCGGGCGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
GCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
CGCGCTCCGAAAGTTTCCCTTTTATGGCGAGGCGGCGGCGGCGGCCCTATAAAA  
AGCGAAGCGCGCGGGCGGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGC  
TCCGCCGCCGCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCC  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCAAGTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCGCCACCATGGCCACCGGCTC  
TCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCTTGGCTCCAGGAGGG  
CTCCGCCGCTAGCATCGATACCGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGAGATCTTCGGTTGCACCATGCTCGTTTTTGGCCTCTGACTGACGAGCATGGTGA  
CCGAAGATCTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
CTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGACAGATCTTCGATGTCACCATGCG  
TTTTGGCCTCTGACTGACGCATGGTGACCGAAGATCTGTCAGGACACAAGGCCTGTT  
ACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGACAGATCTTCGAAGTCACCATGCGTTTTTGGCCTCTGACTGACGCATGGTGACC  
GAAGATCTGTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
CTCTAGAAT 3' SEQ ID NO. 11 = SEQ ID NO. 1 + SEQ ID NO. 35'  
AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACATATGTT  
GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
CCCGTATGGCTTTCATTTTCTCCTCCTTGATATAATCCTGGTTGCTGTCTCTTTATGAG  
GAGTTGTGGCCCGTTGTCAAGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA  
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCGGGGACTTTCGCTT  
TCCCCCTCCCTATTGCCACGGCGGAACATCGCCGCCTGCCTTGCCCGCTGCTGGA  
CAGGGGCTCGGCTGTTGGGCACTGACAATTCGTGGTGTGTCGGGGAAATCATCGT  
CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
CTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCT  
CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
CCGCCTCCCCGCCTAAGCTTATCGATACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTT  
CACTGCATTCTAGTTGTGGTTTGTCCAACTCATCAATGTATCTTATCATGTCTGGAT  
CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATTA  
ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
TCACTGAGGCCGGGCGACCAAAGGTGCGCCGACGCCCGGGCTTTGCCCGGGCGGGC  
TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGCAATGGCTG  
GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTGCGCCGGCTTTCGCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT

TTAATGATGGACTCTGTCTTCAACCAACCACTCACTCCATCGGCTCTTATCT  
TTTTGATTTATAAGGGATTTTGGCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATT  
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT  
GCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAA  
TATATGAGGGTTCTAAAAATTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCTGTATGATTTATTGGATGTTGGA  
ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATGG  
TGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTTACCGTTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTGCGCCCTTATTCCCTTTTTTGGCGGCATTTTGCCTTCTGTTTTTGGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACTATTCTCAGAATGACTTGGTTGAG  
TACTCACCGATCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAATC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGCGGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGG  
AGCCTATGGA AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT

[illegible]



[illegible]

TTGTTTGGTCCGATCAAGAGTACCAACTACTTTTTTCCGAAGGTAAGTGGCTTCCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGGCGG  
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTTGCTGG  
CCTTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCCGGG  
CAAAGCCCCGGGCGTTCGGGCGACCTTTGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACCTCCATCACTAGGGGGTTCCTTGTAGTTAATGATTAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTAATTTATTTATTTTTTAATTTTGT  
TGCAGCGATGGGGGCGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGGGGGCGGG  
GCGAGGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
CGCGCTCCGAAAGTTTTCTTTTTATGGCGAGGCGGGCGGCGGCGGCCCTATAAAA  
AGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGC  
TCCGCCGCCGCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCCG  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCAAGTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCGCCACCATGGCCACCGGCTC  
TCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCTTGGCTCCAGGAGGG  
CTCCGCCGCTAGCATCGATAACGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGATAGTTCGGGCTGTCAGAATTCGTTTTTGGCCTCTGACTGACGAAATTCAG  
CCCGAACTATCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
CTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGAGATGAATGCCTGATAGCCTTCCG  
TTTTGGCCTCTGACTGACGGAAGGCTATGGCATTCTCATCTCAGGACACAAGGCCTGTT  
ACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGAGATGAATGCCAATAGCCTTCCGTTTTTGGCCTCTGACTGACGGAAGGCTATG  
GCATTCTATCTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTC  
TCTAGAAT 3' SEQ ID NO. 13 = SEQ ID NO. 1 + SEQ ID NO. 5'  
AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT  
GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
CCCGTATGGCTTTCATTTTCTCCTCCTTGATATAAATCCTGGTTGCTGTCTCTTTATGAG  
GAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA

ACCCCACTGTTGGGGGCACTGCCACCACTGTGACAGTCTTTTCCGGGACTTTTCGCTT  
TCCCCCTCCCTATTGCCACGGCGGAACATCATCGCCGCCTGCCTTGCCCCGCTGCTGGA  
CAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTGTCGGGGAAATCATCGT  
CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
CTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGGCCTGCTGCCGGCT  
CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
CCGCCTCCCCGCCTAAGCTTATCGATACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTT  
CACTGCATTCTAGTTGTGGTTTGTCCAACTCATCAATGTATCTTATCATGTCTGGAT  
CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATT  
ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
TCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCC  
TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGCAATGGCTG  
GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTGCGCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
TTAATAGTGGACTCTTGTTCCAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
TTTTGATTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATT  
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT  
GCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAA  
TATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATCTTTGCCTTGCTGTATGATTTATTGGATGTTGGA  
ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGGCATATGG  
TGCACCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTGCCCCTTATTCCCTTTTTTTCGGGCATTTTGCCTTCCTGTTTTTTGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACTATTCTCAGAATGACTTGGTTGAG  
TACTCACAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT

CGGAGGACCGGAGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAAGTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGTGTGAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTT  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCAGGGTTGGACTCAAGACGATAGTTACCAGGA  
TAAGGCGCAGCGGTTCGGGCTGAACGGGGGGGTTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGGCGG  
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGG  
CAAAGCCCCGGGCGTCGGGCGACCTTTGGTTCGCCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTTGTAGTTAATGATTAAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCG  
CCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG  
TGCAGCGATGGGGGGCGGGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGCGGGGGGGGG  
GCGAGGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
CGCGCTCCGAAAGTTTCTTTTATGGCGAGGCGGCGGGCGGCGGCGGCCCTATAAAA  
AGCGAAGCGCGCGGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGC  
TCCGCCGCCGCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCC  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCACTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCGCCACCATGGCCACCGGCTC  
TCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCTTGGCTCCAGGAGGG  
CTCCGCCGCTAGCATCGATACCGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTAT

GCTGTTCCAGATCATCATCTGGGTATCCCGGCGTGTTTGGCCTCTGACTGACGCCGGGATACCCG  
 ATGATCTGAACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
 CTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGAATAATCAGATGGTGTGCGATCG  
 TTTTGGCCTCTGACTGACGATCGCAACACCCTGATTATTCAGGACACAAGGCCTGTT  
 ACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTAT  
 GCTGTACTGATGCACAATTTAAACGCCGTTTTGGCCTCTGACTGACGGCGTTTAAAG  
 TGCATCAGTACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
 CTCTAGAAT 3' SEQ ID NO. 14 = SEQ ID NO. 1 + SEQ ID NO. 65'  
 AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT  
 GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
 CCCGTATGGCTTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAG  
 GAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA  
 ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTT  
 TCCCCCTCCCTATTGCCACGGCGGAACATCGCCGCCTGCCTTGCCCGCTGCTGGA  
 CAGGGGCTCGGCTGTTGGGCACTGACAATTCGTGGTGTGTCGGGGAAATCATCGT  
 CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
 CTACGTCCCTTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCT  
 CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
 CCGCCTCCCCGCCTAAGCTTATCGATACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
 ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTT  
 CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGAT  
 CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATT  
 ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
 TCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCC  
 TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
 CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGCAATGGCTG  
 GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
 AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
 ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
 CTGGCGTACCGTTCCTGTCTAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
 TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
 CCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
 TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
 ACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
 TTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
 AGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
 TTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
 TTTTGATTTATAAGGGATTTTGGCGATTTCCGGCCTATTGGTTAAAAAATGAGCTGATT  
 TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT  
 GCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
 TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
 AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
 ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
 GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTAAAA  
 TATATGAGGGTTCTAAAAATTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
 AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
 CTTTATTGCTTAATTTTGCTAATTTCTTTGCCTTGCTGTATGATTATTGGATGTTGGA  
 ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATATGG  
 TGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
 CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA

CAAGCTGTGCTGCTCTCCGGGAGCTGTGTGACAGGTTTTCACGGTCACGG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTGCGCCCTTATTCCTTTTTTTCGGGCATTTTGCCCTTCTGTTTTTGTCTACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACTATTCTCAGAATGACTTGGTTGAG  
TACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCTC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTG TAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTGCGGGCTGAACGGGGGGGTTCTGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGG  
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGG  
CAAAGCCCGGGCGTCGGGCGACCTTTGGTGCGCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTGTAGTTAATGATTAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTAAATTATTTT  
TGCAGCGATGGGGGCGGGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGCGGGG  
GCGAGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG

CGCGCTCCGCGAAAGTTTCTCTTTTATGGCGAGGAGCGGCGCGCGCGCGGCCGCCCTATAAAA  
AGCGAAGCGCGCGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGC  
TCCGCCGCCGCCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCC  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCAAGTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCATGGCCACCGGCTCTCGCAC  
AAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCTTGGCTCCAGGAGGGCTCCGC  
CGCTAGCATCGATAACCGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTATGCTGAG  
GTAATCGGCTGATGCGTTTGCGTTTTGGCCTCTGACTGACGCAAACGCATGCCGATT  
ACCTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTAGCCT  
GGAGGCTTGCTGAAGGCTGTATGCTGTTATACACGGTATGCCTTTCAGCGTTTTTGGC  
CTCTGACTGACGCTGAAAGGCACCGTGTATAACAGGACACAAGGCCTGTTACTAGC  
ACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGAT  
CAGATCATCAAGTTCAGCAGCGTTTTTGGCCTCTGACTGACGCTGCTGAACGATGATC  
TGATCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTCTCTAGA AT  
3' SEQ ID NO. 15 = SEQ ID NO. 1 + SEQ ID NO. 75'  
AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT  
GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAG  
GAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA  
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCGGGGACTTTCGCTT  
TCCCCCTCCCTATTGCCACGGCGGAACCTCATCGCCGCCTGCCTTGCCCCGCTGCTGGA  
CAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTCGGGGAAATCATCGT  
CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
CTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCT  
CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
CCGCCTCCCCGCCTAAGCTTATCGATAACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTT  
CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGAT  
CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATT  
ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
TCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCC  
TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTGCAATGGCTG  
GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
TTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
TTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATT

ACCAAAATTTAAACGCGAATTTTAAACAAATATTAACAGTTTACAATTTAAATATT  
GCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAA  
TATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGATTTATTGGATGTTGGA  
ATTCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATATGG  
TGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGGTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTGCGCCCTTATTCCTTTTTTTCGGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAG  
TACTCACAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAATC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTTAATTTAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTCTGGGCTGAACGGGGGGTTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCTGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGGCGG  
AGCCTATGGA AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGG



[illegible]

CGCGTAATATTGTTCTGGATATTACAGCAAGAGCCGATAGTTTGTAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
TTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
TTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATT  
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT  
GCTTATACAATCTTCCTGTTTTTGGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAA  
TATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGATTTATTGGATGTTGGA  
ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATGG  
TGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGTTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTCGCCCTTATTCCCTTTTTTTCGGGCATTTTGCCTTCCTGTTTTTGTCTACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAG  
TACTCACCAAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAATC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC  
ACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACT  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA

AACTCTGTAGCACCACCGCTACATACCTACCTCGCTGCTAATCCTGTTTACCAGTGGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTTCGGGCTGAACGGGGGGGTTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTTGTGATGCTCGTCAGGGGGGGCGG  
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGG  
CCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCCGGG  
CAAAGCCCCGGGCGTCGGGCGACCTTTGGTTCGCCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTTGTAGTTAATGATTAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTTCTACTTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG  
TGCAGCGATGGGGGGCGGGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGCGGGGGGGGG  
GCGAGGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
CGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCGGCCCTATAAAA  
AGCGAAGCGCGCGGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCCGTGCCCCGC  
TCCGCCGCCGCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCC  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCAGTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCGCCACCATGGCCACCGGCTC  
TCGCACAAGCCTGCTGCTGGCTTTCGGACTGCTGTGCCTGCCTTGGCTCCAGGAGGG  
CTCCGCCGCTAGCATCGATACCGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGATACAGGCGTTTTGTGCTCGGTTTCGTTTTGGCCTCTGACTGACGAACCGAGCAA  
ACGCCTGTATCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCT  
CTAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGTCATGATCAATATGGTATCCGGCG  
TTTTGGCCTCTGACTGACGCCGGATAACCATTGATCATGACAGGACACAAGGCCTGTT  
ACTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGTCATGATCAATAAGGTATCCGGCGTTTTTGGCCTCTGACTGACGCCGGATACCA  
TTGATCATGACAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTC  
TCTAGAAT 3' SEQ ID NO. 17 = SEQ ID NO. 1 + SEQ ID NO. 95'  
AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT  
GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT  
CCCGTATGGCTTTTCATTTTCTCCTCCTTGATAAATCCTGGTTGCTGTCTCTTTATGAG  
GAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA  
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTT  
TCCCCCTCCCTATTGCCACGGCGGAACCTATCGCCGCCTGCCTTGCCCCGCTGCTGGA

CAGGGGCTCGGCTGCTGGCTGACCAATTCCTGGTGTGTCGGGGAATCAGT  
CCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTG  
CTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCT  
CTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGG  
CCGCCTCCCCGCCTAAGCTTATCGATACCGTCGAGATCTAACTTGTTTATTGCAGCTT  
ATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTT  
CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGAT  
CTCGACCTCGACTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATT  
ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGC  
TCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGGC  
TCAGTGAGCGAGCGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCG  
CCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGCAATGGCTG  
GCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTC  
AGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG  
ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATT  
CTGGCGTACCGTTCCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTC  
TGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCG  
CCCTGTAGCGGCGCATTAAAGCGCGGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC  
TACACTTGCCAGCGCCCTAGCGCCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC  
ACGTTGCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGA  
TTTAGTGCTTTACGGCACCTCGACCCCCAAAAAACTTGATTAGGGTGATGGTTCACGT  
AGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCT  
TTAATAGTGGA CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTC  
TTTTGATTATAAGGGATTTTGCCGATTTGCGCCTATTGGTTAAAAAATGAGCTGATT  
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTT  
GCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA  
TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTC  
AGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCCTCTCCGGC  
ATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC  
GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAA  
TATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAA  
AAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG  
CTTTATTGCTTAATTTTGCTAATCTTTGCCTTGCTGTATGATTTATTGGATGTTGGA  
ATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATGG  
TGC ACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCG  
CCAACACCCGCTGACGCGCCCTGACGGGCTTGCTGTCTCCCGGCATCCGCTTACAGA  
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGGTCATCACCG  
AAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG  
ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACC  
CCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC  
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC  
GTGTCGCCCTTATTCCTTTTTTTGCGGCATTTTGCTTCCCTGTTTTTGCTCACCCAGAA  
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTT  
TCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC  
GCCGGGCAAGAGCAACTCGGTGCGCCGCATACACTATTCTCAGAATGACTTGGTTGAG  
TACTCACCGATCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG  
CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGAT  
CGGAGGACCGAAGGAGCTAACCGCTTTTTTTGCACAACATGGGGGATCATGTAACCTC  
GCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGAC

ACACGATGCGTACGCTGAGCAATGCGCAACACTGATTGCGCGGCGGCA  
ACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC  
AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGCGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGC  
CCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA  
AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGTGTGAGAC  
CAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTTAATTTAAAAGGA  
TCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTC  
GTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT  
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT  
TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAG  
AGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA  
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGC  
TGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA  
TAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC  
GAACGACCTACACCGAAGTGTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACG  
CTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG  
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTC  
GGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGG  
AGCCTATGGA AAAACGCCAGCAACGCGGCCCTTTTTACGGTTCCTGGCCTTTTTGCTGG  
CCTTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC  
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGT  
CAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGT  
TGGCCGATTCATTAATGCAGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGG  
CAAAGCCCGGGCGTCGGGCGACCTTTGGTTCGCCCGGCCTCAGTGAGCGAGCGAGCG  
CGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTTGTAGTTAATGATTAAC  
CCGCCATGCTACTTATCTACGTAGCCATGCTCTAGGACATTGATTATTGACTAGTGG  
AGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACC  
CCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTT  
TCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATC  
AAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTTCGAGGTGAGCCCCACGTTCTGCTTCACTCTC  
CCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTG  
TGCAGCGATGGGGGCGGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGGCGGGGGGGG  
GCGAGGGGGCGGGGGCGGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGG  
CGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAA  
AGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCGC  
TCCGCCGCCGCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTAAACAG  
GTAAGTCCGGCCTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCAC  
GGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCCGCCC  
GGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCCAAGTAT  
CAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTT  
CCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGG  
ATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT  
TTTTTTTCTACAGGTCCTGGGTGACGAACAGGGTACCGCCACCATGGCCACCGGCTC  
TCGCACAAGCCTGCTGCTGGCTTTCGGAAGTGTGCTGCCTGCCTTGGCTCCAGGAGGG  
CTCCGCCGCTAGCATCGATACCGTCGCTATGTGCTGGAGGCTTGCTGAAGGCTGTAT  
GCTGATAAACAGGCTTGTTTCGCCAGCGTTTTGGCCTCTGACTGACGCTGGGCGAAA  
GCCTGTTTATCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTC

TAGCCTGGAGGCTTGCTGAAGGCTGTATGCTGTTCATAGCTGCAATGGTTTCTTCCGTT  
TTGGCCTCTGACTGACGGAAGAAACCTGCAGCTATGACAGGACACAAGGCCTGTTA  
CTAGCACTCACATGGAACAAATGGCCTCTAGCCTGGAGGCTTGCTGAAGGCTGTATG  
CTGACCACTTCCACAATTCATGCACCGTTTTGGCCTCTGACTGACGGTGCATGAAGT  
GGAAGTGGTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCTC  
TCTAGAAT 3'

[0062] As will be appreciated by those skilled in the art, because the recombinant plasmid is a circular vector, the one or more sequences of the miRNA expression cassettes may be connected at the 3' end of SEQ ID NO. 1, as shown in SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16 and SEQ ID NO. 17, or at the 5' end of SEQ ID NO. 1.

[0063] As will be appreciated by those skilled in the art, a perfect match of nucleotides with each of the miRNA expression cassette sequences is not necessary in order to have the desired result of decreased bioavailability of the target biomolecule as a result of the target cell producing the miRNA sequence that will bind to and degrade the mRNA of the target biomolecule. In some embodiments of the present disclosure, about 80% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 85% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 90% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 95% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result.

#### Example 1—Expression Cassette

[0064] Expression cassettes for expressing miRNA were synthesized. The synthesized miRNA expression cassettes were cloned into the pAVA-00200 plasmid backbone containing the CASI promoter, multiple cloning site (MCS), Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE), and Simian virus 40 (SV40) polyadenylation (polyA) sequence, all flanked by the AAV2 inverted terminal repeats (ITR). pAVA-00200 was cut with the restriction enzymes KpnI and XbaI in the MCS and separated on a 1% agarose gel. The band of interest was excised and purified using a gel extraction kit. Each miRNA expression cassette was amplified by polymerase chain reaction (PCR) using Taq polymerase and the PCR products were gel purified and the bands on interest were also excised and purified using a gel extraction kit. These PCR products contained the miRNA expression cassettes in addition to 15 base pair 5' and 3' overhangs that aligned with the ends of the linearized pAVA-00200 backbone. Using in-fusion cloning, the amplified miRNA expression cassettes were integrated with the pAVA-00200 backbone via homologous recombination. The resulting RP contained the following: 5' ITR, CASI promoter, miRNA expression cassette, WPRE, SV40 polyA and ITR 3'.

## Claims

1. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes a complement C1g, and wherein the sequence of nucleotides is SEQ ID NO. 2.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

- 9. (canceled)
  - 10. (canceled)
  - 11. The composition of claim 1, wherein the sequence of nucleotides is encased in a protein coat, a lipid vesicle or a viral vector.
  - 12. The composition of claim 11, wherein the viral vector is one of a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.
  - 13. The composition of claim 12, wherein the viral vector is an adeno-associated virus.
  - 14. (canceled)
  - 15. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes a complement C1g, and wherein the sequence of nucleotides is SEQ ID NO. 10.
  - 16. (canceled)
  - 17. (canceled)
  - 18. (canceled)
  - 19. (canceled)
  - 20. (canceled)
  - 21. (canceled)
  - 22. (canceled)
  - 23. (canceled)
-